Skip to content
2000
Volume 17, Issue 2
  • ISSN: 2589-9775
  • E-ISSN: 2589-9783

Abstract

Background

Rheumatoid Arthritis (RA) is a systemic inflammatory auto-immune disorder chiefly described by synovitis followed by extra-articular manifestations of organ association such as pneumonia in addition to the clinical symptoms that cause long-term joint damage starting from the small joints and gradually progressing to the larger ones. Early diagnosis is considered a major improvement for the most desirable outcomes. Methotrexate (MTX), an antifolate, has been the gold standard therapy in use for over forty years as an anchor drug. This drug started out as an anti-cancer drug in large doses and is now in use to treat rheumatoid arthritis at very low doses. The treatments for rheumatoid arthritis aim to curb the swelling in the body and protect the joints from further damage. Recent research has seen an increase in the use of combination therapies with Methotrexate.

Objectives

In this paper, we present a summary of the current drug in use and its side effects, associated with RA. The paper gives an account of alternate modes of treatment that have been explored for the treatment of rheumatoid arthritis.

Conclusion

Initially designed to inhibit the enzyme dihydrofolate reductase and treat various types of cancer, methotrexate found application as an anti-rheumatic drug in 1984 although suggestions for the same have been made since the 1950s. Since then, a substantial amount of clinical evidence has been obtained to clearly indicate the cytotoxic activity of the drug against the cells responsible for joint inflammation associated with RA. Thus, methotrexate is a clear choice when it comes to treating RA despite the advent of other lines of treatment being explored and implemented.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775258634231226052204
2025-01-25
2025-10-24

  • From This Site

    /content/journals/cdrr/10.2174/0125899775258634231226052204
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AndersonK.O. BradleyL.A. YoungL.D. McDanielL.K. WiseC.M. Rheumatoid arthritis: Review of psychological factors related to etiology, effects, and treatment.Psychol. Bull.198598235838710.1037/0033‑2909.98.2.3583901066
     [Google Scholar]
  2. SinghN. KumarB. AnjanG. BaghlaA. A review article on rheumatoid arthritis: Patient education.Eur. J. Mol. Clin. Med.20218042021
     [Google Scholar]
  3. GianniniD. AntonucciM. PetrelliF. BiliaS. AlunnoA. PuxedduI. One year in review 2020: Pathogenesis of rheumatoid arthritis.Clin. Exp. Rheumatol.202038338739710.55563/clinexprheumatol/3uj1ng32324123
     [Google Scholar]
  4. CosgroveA. Arthrogryposis: A text atlas. edited by Lynn T Staheli, Judith G Hall, Kenneth M Jaffe, Diane O Paholke.In: £55.00, $85.00 hardback. ISBN 052157165. Developmental Medicine & Child NeurologyCambridgeCambridge University Press.199917841321421410.1017/S0012162299210444
     [Google Scholar]
  5. OngC.K.S. LirkP. TanC.H. SeymourR.A. An evidence-based update on nonsteroidal anti-inflammatory drugs.Clin. Med. Res.200751193410.3121/cmr.2007.69817456832
     [Google Scholar]
  6. Gaujoux-VialaC. SmolenJ.S. LandewéR. DougadosM. KvienT.K. MolaE.M. Scholte-VoshaarM. van RielP. GossecL. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.Ann. Rheum. Dis.20106961004100910.1136/ard.2009.12722520447954
     [Google Scholar]
  7. ConwayR. CareyJ.J. Risk of liver disease in methotrexate treated patients.World J. Hepatol.20179261092110010.4254/wjh.v9.i26.109228989565
     [Google Scholar]
  8. RocheM.L. SamsonK.L.I. GreenT.J. KarakochukC.D. MartinezH. Perspective: Weekly iron and folic acid supplementation (WIFAS): A critical review and rationale for inclusion in the essential medicines list to accelerate anemia and neural tube defects reduction.Adv. Nutr.202112233434210.1093/advances/nmaa16933439978
     [Google Scholar]
  9. CronsteinB.N. Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis.Pharmacol. Rev.200557216317210.1124/pr.57.2.315914465
     [Google Scholar]
  10. KoźmińskiP. HalikP.K. ChesoriR. GniazdowskaE. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers.Int. J. Mol. Sci.20202110348310.3390/ijms2110348332423175
     [Google Scholar]
  11. PreyS. PaulC. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.Br. J. Dermatol.2009160362262810.1111/j.1365‑2133.2008.08876.x18945303
     [Google Scholar]
  12. SchnabelA. GrossW.L. Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects.Semin. Arthritis Rheum.199423531032710.1016/0049‑0172(94)90027‑28036521
     [Google Scholar]
  13. HuennekensF.M. The methotrexate story: A paradigm for development of cancer chemotherapeutic agents.Adv. Enzyme Regul.19943439741910.1016/0065‑2571(94)90025‑67942284
     [Google Scholar]
  14. GubnerR. CoteL. HughesJ. OlesonJ.J. RuegseggerJ.M. WilliamsJ.H. Comparative effects of aminopterin, cortisone and ACTH in experimental formaldehyde arthritis and psoriatic arthritis.J. Invest. Dermatol.195219429730510.1038/jid.1952.10012990838
     [Google Scholar]
  15. BlackR.L. O’BrienW.M. Van ScottE.J. AuerbachR. EisenA.Z. BunimJ.J. Methotrexate therapy in psoriatic arthritis.JAMA19641891074374710.1001/jama.1964.0307010003700714174051
     [Google Scholar]
  16. HoffmeisterR.T. Methotrexate therapy in rheumatoid arthritis: 15 years experience.Am. J. Med.1983756697310.1016/0002‑9343(83)90477‑16660241
     [Google Scholar]
  17. WillkensR.F. Methotrexate treatment of rheumatoid arthritis.Ann. Intern. Med.1985103461261310.7326/0003‑4819‑103‑4‑6124037562
     [Google Scholar]
  18. BraunJ. RauR. An update on methotrexate.Curr. Opin. Rheumatol.200921321622310.1097/BOR.0b013e328329c79d19373092
     [Google Scholar]
  19. AletahaD. NeogiT. SilmanA.J. FunovitsJ. FelsonD.T. BinghamC.O.III BirnbaumN.S. BurmesterG.R. BykerkV.P. CohenM.D. CombeB. CostenbaderK.H. DougadosM. EmeryP. FerraccioliG. HazesJ.M.W. HobbsK. HuizingaT.W.J. KavanaughA. KayJ. KvienT.K. LaingT. MeaseP. MénardH.A. MorelandL.W. NadenR.L. PincusT. SmolenJ.S. Stanislawska-BiernatE. SymmonsD. TakP.P. UpchurchK.S. VencovskýJ. WolfeF. HawkerG. 2010 Rheumatoid arthritis classification criteria: An american college of rheumatology/european league against rheumatism collaborative initiative.Arthritis Rheum.20106292569258110.1002/art.2758420872595
     [Google Scholar]
  20. CurtisJ.R. SinghJ.A. Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care.Clin. Ther.201133667970710.1016/j.clinthera.2011.05.04421704234
     [Google Scholar]
  21. InoueK. YuasaH. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy.Drug Metab. Pharmacokinet.2014291121910.2133/dmpk.DMPK‑13‑RV‑11924284432
     [Google Scholar]
  22. VisserK. van der HeijdeD. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: A systematic review of the literature.Ann. Rheum. Dis.20096871094109910.1136/ard.2008.09266819033290
     [Google Scholar]
  23. BedouiY. GuillotX. SélambaromJ. GuiraudP. GiryC. Jaffar-BandjeeM.C. RalandisonS. GasqueP. Methotrexate an old drug with new tricks.Int. J. Mol. Sci.20192020502310.3390/ijms2020502331658782
     [Google Scholar]
  24. TugwellP. PincusT. YocumD. SteinM. GluckO. KraagG. McKendryR. TesserJ. BakerP. WellsG. The Methotrexate-Cyclosporine Combination Study Group Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis.N. Engl. J. Med.1995333313714210.1056/NEJM1995072033303017791814
     [Google Scholar]
  25. O’DellJ.R. HaireC.E. EriksonN. DrymalskiW. PalmerW. EckhoffP.J. GarwoodV. MaloleyP. KlassenL.W. WeesS. KleinH. MooreG.F. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.N. Engl. J. Med.1996334201287129110.1056/NEJM1996051633420028609945
     [Google Scholar]
  26. HuangR. PanH. WuJ. ZhouH. LiZ. QiuP. ZhouY. ChenX. XieZ. XiaoY. HuangQ. LiuL. Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.Phytomedicine20195740341010.1016/j.phymed.2018.12.03030851515
     [Google Scholar]
  27. WeinblattM.E. Methotrexate in rheumatoid arthritis: A quarter century of development.Trans. Am. Clin. Climatol. Assoc.2013124162523874006
     [Google Scholar]
  28. HanrahanP.S. ScrivensG.A. RussellA.S. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: Toxicity, efficacy and radiological progression.Rheumatology198928214715310.1093/rheumatology/28.2.1472706419
     [Google Scholar]
  29. WeinblattM.E. WeissmanB.N. HoldsworthD.E. FraserP.A. MaierA.L. FalchukK.R. CoblyJ.S. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.Arthritis Rheum.199235212913710.1002/art.17803502021734901
     [Google Scholar]
  30. BeyelerC. [Methotrexate treatment of rheumatoid arthritis].Schweiz. Med. Wochenschr.199612617703712[Methotrexate treatment of rheumatoid arthritis].8668981
     [Google Scholar]
  31. AliM.L. AlamM.N. HaqS.A. DasK.K. BaralP.K. Efficacy of methotrexate in rheumatoid arthritis.Bangladesh Med. Res. Counc. Bull.199723372769621475
     [Google Scholar]
  32. GaiesE. JebabliN. Methotrexate side effects: Review article.J. Drug Metab. Toxicol.20123410.4172/2157‑7609.1000125
     [Google Scholar]
  33. FreiE.III BlumR.H. PitmanS.W. KirkwoodJ.M. HendersonI.C. SkarinA.T. MayerR.J. BastR.C. GarnickM.B. ParkerL.M. CanellosG.P. High dose methotrexate with leucovorin rescue.Am. J. Med.198068337037610.1016/0002‑9343(80)90105‑96965819
     [Google Scholar]
  34. HankeyG.J. EikelboomJ.W. Homocysteine and stroke.Curr. Opin. Neurol.20011419510210.1097/00019052‑200102000‑0001511176224
     [Google Scholar]
  35. AlmalkiR.S. EweisH. KamalF. KutbiD. Methotrexate toxicity: Molecular mechanisms and management.J. Pharm. Res. Int.2021•••20421710.9734/jpri/2021/v33i49B33357
     [Google Scholar]
  36. HamedK.M. DighririI.M. BaomarA.F. AlharthyB.T. AlenaziF.E. AlaliG.H. AlenazyR.H. AlhumaidiN.T. AlhulayfiD.H. AlotaibiY.B. AlhumaidanS.S. AlhaddadZ.A. HumadiA.A. AlzahraniS.A. AlobaidR.H. Overview of methotrexate toxicity: A comprehensive literature review.Cureus2022149e2951810.7759/cureus.2951836312688
     [Google Scholar]
  37. CronsteinB.N. NaimeD. OstadE. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.J. Clin. Invest.19939262675268210.1172/JCI1168848254024
     [Google Scholar]
  38. ZachariaeH. Methotrexate side-effects.Br. J. Dermatol.1990122s36Suppl. 3612713310.1111/j.1365‑2133.1990.tb02890.x2196079
     [Google Scholar]
  39. MainiR.N. FeldmannM. How does infliximab work in rheumatoid arthritis?Arthritis Res.20024Suppl 2Suppl. 2S22S2810.1186/ar54912110154
     [Google Scholar]
  40. TanakaY. Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis.Expert Opin. Biol. Ther.202323757958710.1080/14712598.2023.223134437431762
     [Google Scholar]
  41. BombardieriS. RuizA.A. FardelloneP. GeusensP. McKennaF. UnnebrinkK. OezerU. KaryS. KupperH. BurmesterG.R. Research in Active Rheumatoid Arthritis (ReAct) Study Group Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.Rheumatology20074671191119910.1093/rheumatology/kem09117504821
     [Google Scholar]
  42. JarvisB. FauldsD. Etanercept.Drugs199957694596610.2165/00003495‑199957060‑0001410400407
     [Google Scholar]
  43. RichezC. TruchetetM.E. SchaeverbekeT. BannwarthB. Atacicept as an investigated therapy for rheumatoid arthritis.Expert Opin. Investig. Drugs20142391285129410.1517/13543784.2014.94383525078871
     [Google Scholar]
  44. GenoveseM.C. BojinS. BiaginiI.M. MociranE. CristeiD. MireaG. GeorgescuL. Sloan-LancasterJ. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: A phase II, randomized, placebo-controlled trial.Arthritis Rheum.201365488088910.1002/art.3782023359344
     [Google Scholar]
  45. MokC.C. Rituximab for the treatment of rheumatoid arthritis: An update.Drug Des. Devel. Ther.201388710010.2147/DDDT.S4164524403823
     [Google Scholar]
  46. CohenM.D. KeystoneE. Rituximab for rheumatoid arthritis.Rheumatol. Ther.2015229911110.1007/s40744‑015‑0016‑927747531
     [Google Scholar]
  47. Ruyssen-WitrandA. RouanetS. CombeB. DougadosM. Le LoëtX. SibiliaJ. TebibJ. MarietteX. ConstantinA. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.Rheumatology201352463664110.1093/rheumatology/kes34423264555
     [Google Scholar]
  48. Ruyssen-WitrandA. RouanetS. CombeB. DougadosM. Le LoëtX. SibiliaJ. TebibJ. MarietteX. ConstantinA. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.Ann. Rheum. Dis.201271687587710.1136/annrheumdis‑2011‑20033722368231
     [Google Scholar]
  49. JonesG. PanovaE. New insights and long-term safety of tocilizumab in rheumatoid arthritis.Ther. Adv. Musculoskelet. Dis.2018101019519910.1177/1759720X1879846230327685
     [Google Scholar]
  50. RamírezJ. CañeteJ.D. Anakinra for the treatment of rheumatoid arthritis: A safety evaluation.Expert Opin. Drug Saf.201817772773210.1080/14740338.2018.148681929883212
     [Google Scholar]
  51. Marije I Koenders & Wim B van den Berg Secukinumab for rheumatology: Development and its potential place in therapyDrug Des Devel Ther2016102069208010.2147/DDDT.S105263
     [Google Scholar]
  52. GazeauP. AlegriaG.C. Devauchelle-PensecV. JaminC. LemerleJ. BendaoudB. BrooksW.H. SarauxA. CornecD. RenaudineauY. Memory B cells and response to abatacept in rheumatoid arthritis.Clin. Rev. Allergy Immunol.201753216617610.1007/s12016‑017‑8603‑x28477078
     [Google Scholar]
  53. ReginsterJ.Y.L. CONCEPT Investigation Group CONCEPT provides robust evidence that chondroitin sulfate is superior to placebo and similar to celecoxib in the symptomatic management of osteoarthritis.Ann. Rheum. Dis.2018772e1110.1136/annrheumdis‑2017‑21216528939627
     [Google Scholar]
  54. RengasamyK.R.R. KhanH. GowrishankarS. LagoaR.J.L. MahomoodallyF.M. KhanZ. SuroowanS. TewariD. ZenginG. HassanS.T.S. PandianS.K. The role of flavonoids in autoimmune diseases: Therapeutic updates.Pharmacol. Ther.201919410713110.1016/j.pharmthera.2018.09.00930268770
     [Google Scholar]
  55. SanchezP. LetarouillyJ.G. NguyenY. SigauxJ. BarnetcheT. CzernichowS. FlipoR.M. SellamJ. DaïenC. Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: A systematic review and meta-analysis of randomized controlled trials.Nutrients202214235410.3390/nu1402035435057535
     [Google Scholar]
  56. MurdacaG. TonacciA. NegriniS. GrecoM. BorroM. PuppoF. GangemiS. Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications.Autoimmun. Rev.201918910235010.1016/j.autrev.2019.10235031323357
     [Google Scholar]
  57. LiuY. AlookaranJ. RhoadsJ. Probiotics in autoimmune and inflammatory disorders.Nutrients20181010153710.3390/nu1010153730340338
     [Google Scholar]
  58. TiwariP. Nutraceuticals as supplements in the management of arthritis: A review.International Journal of Pharmaceutical Research202013110.31838/ijpr/2021.13.01.074
     [Google Scholar]
  59. HulekarS. PoolyaM.C. Effect of homoepathy in management of rheumatoid arthritis.Journal of Medical and Pharmaceutical Innovation2022946
     [Google Scholar]
  60. PriyankaD. MishraD.K. SinghD.J. Can individualized homoeopathic medicines bring a ray of hope the patients of rheumatoid arthritis: A pilot study.International Journal of Homoeopathic Sciences20226416517110.33545/26164485.2022.v6.i4c.655
     [Google Scholar]
  61. KunduN. DeM. SinghS. MichaelJ. NathA. MagotraN. KoleyM. SahaS. Homeopathic treatment of rheumatoid arthritis: An open, observational trial.Homoeopathic Links201932421622310.1055/s‑0039‑3402080
     [Google Scholar]
  62. BrienS. LachanceL. PrescottP. McDermottC. LewithG. Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: A randomized controlled clinical trial.Rheumatology20115061070108210.1093/rheumatology/keq23421076131
     [Google Scholar]
  63. RastogiS. Emanating the specialty clinical practices in Ayurveda: Preliminary observations from an arthritis clinic and its implications.J. Ayurveda Integr. Med.2021121525710.1016/j.jaim.2019.09.00932247569
     [Google Scholar]
  64. BaigS. DiRenzoD.D. Complementary and alternative medicine use in rheumatoid arthritis.Curr. Rheumatol. Rep.202022106110.1007/s11926‑020‑00938‑z32845419
     [Google Scholar]
  65. LindlerB.N. LongK.E. TaylorN.A. LeiW. Use of herbal medications for treatment of osteoarthritis and rheumatoid arthritis.Medicines (Basel)20207116710.3390/medicines711006733126603
     [Google Scholar]
  66. SultanaF. AroraB. AroraS. SindhuK. Comprehensive review on ayurvedic formulations and herbal medicines for treatment of rheumatoid arthritis.Journal of University of Shanghai for Science and Technology2021230777279010.51201/JUSST/21/07218
     [Google Scholar]
  67. MishraG. PandyaD.H. Efficacy of erand sneha (castor oil) in the management of amavata (rheumatoid arthritis) with respect to its sama stage.Journal of research in traditional medicine2017322828
     [Google Scholar]
  68. De SilvaG. T. S. R. EdiriweeraE. R. H. S. S. Effect of Virechana Karma using Eranda Taila, Followed by Murva Dahaya Kashaya, Bimtambaru Sweda and Bimtambaru Patra Lepa on Rheumatoid Arthritis (Amavata)–A Case Report.In: International Journal of AYUSH Case Reports202164371377Retrieved from https://www.ijacare.in/index.php/ijacare/article/view/376
     [Google Scholar]
  69. PagliaM.D.G. SilvaM.T. LopesL.C. Barberato-FilhoS. MazzeiL.G. AbeF.C. de Cássia BergamaschiC. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis.PLoS One2021164e024886610.1371/journal.pone.024886633826610
     [Google Scholar]
  70. XieP. XueW. QiW. LiY. YangL. YangZ. ShiA. Safety, tolerability, and pharmacokinetics of Ibuprofenamine hydrochloride spray (nsaids), a new drug for rheumatoid arthritis and osteoarthritis, in healthy Chinese subjects.Drug Des. Devel. Ther.20211562963810.2147/DDDT.S29484933628011
     [Google Scholar]
  71. KołodziejskaJ. KołodziejczykM. Diclofenac in the treatment of pain in patients with rheumatic diseases.Reumatologia201856317418310.5114/reum.2018.7681630042605
     [Google Scholar]
  72. AtzeniF. MasalaI.F. BagnascoM. LanataL. MantelliF. Sarzi-PuttiniP. Comparison of efficacy of ketoprofen and ibuprofen in treating pain in patients with rheumatoid arthritis: A systematic review and meta-analysis.Pain Ther.202110157758810.1007/s40122‑021‑00250‑333674957
     [Google Scholar]
  73. Micheli Bozdag Akgul Carta Guccione Bergonzi Bilia Cinci Lucarini Parisio Supuran Ghelardini Di Cesare Mannelli Micheli, Bozdag, Akgul, Carta, Guccione, Bergonzi, Bilia, Cinci, Lucarini, Parisio, Supuran, Ghelardini, & Di Cesare Mannelli. (2019). Pain relieving effect of-nsaids-cais hybrid molecules: Systemic and intra-articular treatments against rheumatoid arthritis.Int. J. Mol. Sci.2019208192310.3390/ijms20081923
     [Google Scholar]
  74. DennisonE.M. CooperC. Corticosteroids in rheumatoid arthritis.BMJ1998316713478979010.1136/bmj.316.7134.7899549442
     [Google Scholar]
  75. HuaC. ButtgereitF. CombeB. Glucocorticoids in rheumatoid arthritis: Current status and future studies.RMD Open202061e00053610.1136/rmdopen‑2017‑00053631958273
     [Google Scholar]
  76. YoshiiI. SawadaN. Efficacy and safety of intra-articular injection with triamcinolone acetonide for patients with rheumatoid arthritis.Drugs Ther. Perspect.202036940441210.1007/s40267‑020‑00755‑5
     [Google Scholar]
  77. RubinS. OhanaO. GoldbergO. PeledO. GendlerY. Habot-WilnerZ. LevinskyY. TalR. HarelL. AmarilyoG. The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis.Pediatr. Rheumatol. Online J.2022201510.1186/s12969‑022‑00666‑x35093116
     [Google Scholar]
  78. MaityS. MisraA. WairkarS. Novel injectable carrier based corticosteroid therapy for treatment of rheumatoid arthritis and osteoarthritis.J. Drug Deliv. Sci. Technol.20216110230910.1016/j.jddst.2020.102309
     [Google Scholar]
  79. ZhangX. WuX. ChenL. HeL. Autoimmune diseases and risk of gestational diabetes mellitus: A Mendelian randomization study.Acta Diabetol.202310.1007/s00592‑023‑02190‑037804336
     [Google Scholar]
  80. Andrea Cortés-LadinoC. Augusto Arias-OrtizW. Porras-RamírezA. Effectiveness of yoga and acupuncture in rheumatoid arthritis: A systematic review and meta-analysis.Evid. Based Complement. Alternat. Med.2023202311010.1155/2023/909844237842334
     [Google Scholar]
  81. AliA. JoriC. Kanika KumarA. KhanR. Recent trends in stimuli-responsive hydrogels for the management of rheumatoid arthritis.J. Drug Deliv. Sci. Technol.20238910498510.1016/j.jddst.2023.104985
     [Google Scholar]
  82. RaduA.F. BungauS.G. Nanomedical approaches in the realm of rheumatoid arthritis.Ageing Res. Rev.20238710192710.1016/j.arr.2023.10192737031724
     [Google Scholar]
/content/journals/cdrr/10.2174/0125899775258634231226052204
Loading
The Journey of Methotrexate and Potential Alternative Pharmacotherapies for Rheumatoid Arthritis
Current Drug Research Reviews 17, 142 (2025); https://doi.org/10.2174/0125899775258634231226052204
/content/journals/cdrr/10.2174/0125899775258634231226052204
/content/journals/cdrr/10.2174/0125899775258634231226052204
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): alternative treatments; DMARDs; history; methotrexate; pharmacokinetics; Rheumatoid arthritis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test